Clinical trial of recombinant herpes zoster ZFA01 adjuvant vaccine (CHO cells) approved
February 10, 2026
Source: drugdu
30
On February 9, Zhifei Biological Products Co., Ltd. announced that it had recently learned that the recombinant herpes zoster ZFA01 adjuvant vaccine (CHO cell) developed by its wholly-owned subsidiary Zhifei Longcom has received a drug clinical trial approval notice from the National Medical Products Administration, agreeing to conduct clinical trials for the prevention of herpes zoster in people aged 40 and above.
If the project progresses smoothly, it will further enrich Zhifei Biological's adult vaccine portfolio and improve its product portfolio. However, it should be noted that drug development is characterized by large investments, long cycles, and high risks, and there are uncertainties regarding the progress, results, and market launch of subsequent clinical trials.
This vaccine uses a novel, independently developed adjuvant that can simultaneously stimulate both cellular and humoral immune responses, potentially enhancing its protective efficacy. However, the shingles vaccine market is highly competitive, and its commercial performance remains to be seen.
https://www.nbd.com.cn/articles/2026-02-09/4255677.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- The first subject has been dosed in the Phase I clinical trial of Yuandong Bio’s EP-0210 monoclonal antibody injection. February 10, 2026
- Heyu Pharmaceuticals’ FGFR4 inhibitor ipagoglottinib has received Fast Track designation from the FDA for the treatment of advanced HCC patients with FGF19 overexpression who have been treated with ICIs and mTKIs. February 10, 2026
- Sanofi’s “Rilzabrutinib” has been recognized as a Breakthrough Therapy in the United States and an Orphan Drug in Japan, and has applied for marketing approval in China. February 10, 2026
- Domestically developed blockbuster ADC approved for new indication February 10, 2026
- Novartis’s first-ever autoimmune drug has been submitted for marketing approval in China. February 10, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
